AVAV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AVAV is a good buy right now for a beginner-focused long-term investor with $50,000-$100,000, and I would take the buy. The stock has strong fresh catalysts, a powerful earnings-driven breakout, and supportive analyst coverage despite some target cuts. Since the user is impatient and not waiting for a perfect entry, this is still an acceptable entry after the recent surge because the contract win and FY27 growth outlook materially improve the long-term thesis.
AVAV is in a strong short-term upward trend. MACD histogram is positive and expanding, which supports momentum continuation. RSI_6 at 77.696 is elevated, showing the stock has already run hard, but the market structure still favors strength after the breakout. The moving averages remain bearish overall (SMA_200 > SMA_20 > SMA_5), which means the longer-term trend has not fully reversed yet, but the recent price jump above key levels suggests a transition phase. Price at 191.41 is above pivot 163.668 and just under R1 188.566 after a large move, with next upside reference at R2 203.949. The stock trend estimate also points to a positive near-term bias.
The biggest catalyst is the newly secured $500 million U.S. Army fixed-price contract for counter-unmanned aerial systems, which strengthens revenue visibility and improves the long-term defense growth story. Recent earnings were also strong, and the company’s FY27 guidance points to about 10% revenue growth at the midpoint with continued EBITDA expansion. Wedbush initiated coverage with an Outperform rating, and other analysts still mostly keep Buy/Outperform views despite lower targets. The market response has been strongly positive, with a major share surge following earnings and the contract news.
There is still legal overhang from the class action lawsuits tied to alleged securities law issues and the terminated Space Force contract. Several analysts cut price targets sharply, showing some caution around near-term execution and margin pressure. The company also faces a bumpy road in space-related revenue and contract timing, and the technical backdrop shows the stock is extended after a sharp rally.
No full financial statement data was provided, but the latest quarter appears very strong. Analysts highlighted strong fiscal Q4 revenue growth, 31% organic growth, and results that beat expectations by 21% on revenue and 14% on earnings. The latest guidance for FY27 implies about 10% revenue growth at the midpoint and EBITDA growth around 14%, which supports a healthy long-term growth outlook. Latest quarter season: fiscal Q4.
Analyst sentiment is still positive overall, with multiple Buy/Outperform ratings intact. However, the trend is clearly toward lower price targets: Jefferies cut to $229, Canaccord to $280, UBS to $166, RBC to $210, Stifel to $220, Clear Street to $247, KeyBanc to $220, and BTIG to $205. The Wall Street pros view is constructive on the business and contract wins, but cautious on near-term margins, award timing, and the Space Force-related reset. Net: bulls remain in charge, but with more conservative targets.
